Micromet, Inc. (NASDAQ: MITI), a transatlantic biopharmaceutical company focused on the development of antibody-based drugs, reports results of a scientific study (1) published in Gynecological Oncology. The findings demonstrate overexpression of the epithelial cell adhesion molecule (EpCAM) as an independent prognostic marker in epithelial ovarian cancer (EOC). The study was a collaboration of Micromet with the Universities of Innsbruck and Linz, both Austria, and Basel, Switzerland.
